Skip to main content

We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.news

SubscribeLogin
Published • loading... • Updated

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

Summary by 24/7 Wall St.
A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.

1 Articles

24/7 Wall St.24/7 Wall St.
Center

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.

·Lakewood, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

24/7 Wall St. broke the news in Lakewood, United States on Thursday, August 13, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Opioids icon

Opioids

Initial Public Offering (IPO) icon

Initial Public Offering (IPO)

California, United States icon

California, United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal